Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus)

Overview


Plain-Language Overview

Rheumatic Fever is an inflammatory disease that can develop after an infection with the bacteria Streptococcus pyogenes, also known as Group A Streptococcus. It mainly affects the heart, joints, skin, and brain. The condition occurs when the body's immune system mistakenly attacks its own tissues, especially the heart valves, following a throat infection. This can lead to symptoms like joint pain, fever, and sometimes heart problems. If untreated, it can cause long-term damage to the heart, known as rheumatic heart disease. The disease primarily affects children and young adults. Early recognition and treatment of the initial infection are important to prevent this complication.

Clinical Definition

Rheumatic Fever is a systemic inflammatory disorder triggered by an autoimmune response to infection with Streptococcus pyogenes (Group A Streptococcus). It typically follows untreated or inadequately treated streptococcal pharyngitis by 2 to 4 weeks. The core pathology involves molecular mimicry, where antibodies against streptococcal antigens cross-react with host tissues, particularly in the heart, joints, skin, and central nervous system. The major clinical significance lies in its potential to cause acute carditis and chronic rheumatic heart disease due to valvular damage. Other manifestations include migratory polyarthritis, Sydenham chorea, erythema marginatum, and subcutaneous nodules. Diagnosis relies on clinical criteria supported by evidence of recent streptococcal infection.

Inciting Event

  • Pharyngeal infection with Streptococcus pyogenes (Group A Streptococcus) initiates the disease.

  • Untreated or partially treated streptococcal pharyngitis triggers the autoimmune response.

  • Exposure to rheumatogenic strains of S. pyogenes with specific M protein serotypes is critical.

Latency Period

  • Symptoms typically develop 2-4 weeks after the initial streptococcal pharyngitis.

  • Latency allows for development of adaptive immune response and cross-reactive antibodies.

  • Delayed onset complicates direct linkage to preceding infection in clinical history.

Diagnostic Delay

  • Nonspecific early symptoms such as fever and malaise lead to misattribution to viral illness.

  • Lack of recent documented streptococcal infection may obscure clinical suspicion.

  • Overlap with other causes of arthritis or carditis delays recognition of rheumatic fever.

  • Variable presentation and absence of pathognomonic tests complicate early diagnosis.

Clinical Presentation


Signs & Symptoms

  • Fever and malaise following untreated or inadequately treated pharyngitis

  • Migratory polyarthritis affecting large joints such as knees and ankles

  • Carditis presenting with chest pain, tachycardia, or heart failure symptoms

  • Erythema marginatum rash appearing on trunk and proximal limbs

  • Sydenham chorea manifesting as involuntary, purposeless movements

History of Present Illness

  • Initial presentation often includes migratory polyarthritis affecting large joints.

  • Fever, fatigue, and malaise precede or accompany joint symptoms.

  • Carditis manifests as chest pain, dyspnea, or palpitations in some patients.

  • Erythema marginatum and subcutaneous nodules may appear later in the course.

  • Sydenham chorea presents as involuntary movements weeks after initial symptoms.

Past Medical History

  • Recent history of untreated or inadequately treated streptococcal pharyngitis is common.

  • Previous episodes of rheumatic fever increase risk of recurrent disease and chronic valvular damage.

  • History of frequent sore throats or streptococcal infections may be present.

  • Lack of prior antibiotic prophylaxis in patients with known rheumatic heart disease worsens prognosis.

Family History

  • Family history of rheumatic fever or rheumatic heart disease suggests genetic susceptibility.

  • Certain HLA class II alleles associated with increased risk may cluster in families.

  • No clear Mendelian inheritance pattern but familial clustering is recognized.

Physical Exam Findings

  • Carditis with a new or changed heart murmur, often a mitral regurgitation murmur

  • Subcutaneous nodules over extensor surfaces such as elbows and knees

  • Erythema marginatum, a nonpruritic, serpiginous rash with central clearing

  • Sydenham chorea, characterized by rapid, involuntary movements and hypotonia

  • Arthritis with swollen, tender, and warm large joints, typically migratory

Diagnostic Workup


Diagnostic Criteria

Diagnosis of rheumatic fever is established using the Jones criteria, which require evidence of recent Group A Streptococcus infection plus the presence of either two major criteria or one major and two minor criteria. Major criteria include carditis, polyarthritis, Sydenham chorea, erythema marginatum, and subcutaneous nodules. Minor criteria include fever, arthralgia, elevated acute phase reactants (ESR or CRP), and prolonged PR interval on ECG. Confirmation of recent streptococcal infection is typically done by positive throat culture, rapid antigen test, or elevated anti-streptolysin O (ASO) titers.

Pathophysiology


Key Mechanisms

  • Molecular mimicry between Streptococcus pyogenes M protein and host tissues triggers autoimmune cross-reactivity.

  • Type II hypersensitivity reaction leads to inflammation of heart, joints, skin, and CNS tissues.

  • Aschoff bodies form as granulomatous lesions in the myocardium causing pancarditis.

  • T-cell mediated immune response contributes to tissue damage in affected organs.

  • Antibody-mediated damage to cardiac myocytes and valves results in chronic valvulitis.

InvolvementDetails
Organs

Heart is the primary organ affected, with inflammation of the endocardium, myocardium, and pericardium causing carditis and valvular damage.

Joints commonly present with migratory arthritis involving large joints such as knees and ankles.

Central nervous system involvement can cause Sydenham chorea characterized by involuntary movements.

Tissues

Cardiac connective tissue is targeted by autoimmune inflammation leading to valvulitis and myocarditis.

Synovial tissue becomes inflamed causing migratory polyarthritis typical of rheumatic fever.

Subcutaneous tissue may develop painless nodules due to localized granulomatous inflammation.

Cells

CD4+ T cells mediate the autoimmune response by recognizing cross-reactive streptococcal antigens and attacking host tissues.

Macrophages participate in granulomatous inflammation forming Aschoff bodies characteristic of rheumatic fever.

B cells produce antibodies against Streptococcus pyogenes that cross-react with cardiac tissue causing molecular mimicry.

Chemical Mediators

Tumor necrosis factor-alpha (TNF-α) promotes inflammation and tissue damage in affected heart valves and joints.

Interleukin-1 (IL-1) contributes to fever and systemic inflammatory response in rheumatic fever.

Anti-streptolysin O (ASO) antibodies serve as serologic markers indicating recent Streptococcus pyogenes infection.

Treatments


Pharmacological Treatments

  • Penicillin

    • Mechanism:
      • Bactericidal antibiotic that inhibits bacterial cell wall synthesis targeting Streptococcus pyogenes.

    • Side effects:
      • Allergic reactions

      • Anaphylaxis

      • Gastrointestinal upset

    • Clinical role:
      • First-line

  • Aspirin

    • Mechanism:
      • Nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes reducing inflammation and fever.

    • Side effects:
      • Gastrointestinal bleeding

      • Tinnitus

      • Allergic reactions

    • Clinical role:
      • Adjunctive

  • Corticosteroids

    • Mechanism:
      • Potent anti-inflammatory agents that suppress immune-mediated tissue damage in severe carditis.

    • Side effects:
      • Immunosuppression

      • Hyperglycemia

      • Osteoporosis

    • Clinical role:
      • Adjunctive

Non-pharmacological Treatments

  • Bed rest during the acute phase to reduce cardiac workload and prevent complications.

  • Long-term prophylaxis with intramuscular benzathine penicillin to prevent recurrent Streptococcus pyogenes infections and rheumatic fever relapse.

Prevention


Pharmacological Prevention

  • Penicillin prophylaxis to eradicate Group A Streptococcus and prevent recurrence

  • Long-term benzathine penicillin G injections every 3-4 weeks for secondary prevention

  • Anti-inflammatory treatment with aspirin or corticosteroids to reduce carditis severity

  • Antibiotic treatment of acute streptococcal pharyngitis to prevent initial rheumatic fever

  • Symptomatic management of chorea with neuroleptics or anticonvulsants if severe

Non-pharmacological Prevention

  • Prompt diagnosis and treatment of streptococcal pharyngitis to prevent immune sequelae

  • Regular cardiac monitoring in patients with history of rheumatic fever

  • Education on adherence to secondary prophylaxis to reduce recurrence risk

  • Avoidance of strenuous physical activity during acute carditis to prevent heart failure

  • Screening family members for streptococcal infections in endemic areas

Outcome & Complications


Complications

  • Chronic rheumatic heart disease with progressive valvular stenosis or regurgitation

  • Heart failure due to severe valvulitis and myocardial involvement

  • Arrhythmias secondary to carditis and conduction system inflammation

  • Infective endocarditis on damaged valves

  • Permanent neurological deficits from severe or prolonged Sydenham chorea

Short-term Sequelae Long-term Sequelae
  • Acute carditis causing pericarditis, myocarditis, or endocarditis

  • Severe migratory arthritis leading to joint pain and limited mobility

  • High fever and systemic inflammation with malaise and fatigue

  • Transient Sydenham chorea impairing motor coordination

  • Skin manifestations such as erythema marginatum and subcutaneous nodules

  • Rheumatic heart disease with chronic valvular deformities, especially mitral stenosis

  • Permanent valvular insufficiency leading to heart failure

  • Increased risk of infective endocarditis on damaged valves

  • Chronic atrial fibrillation due to atrial enlargement from valvular disease

  • Neurological sequelae including persistent chorea or cognitive impairment

Differential Diagnoses


Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus) versus Infective Endocarditis

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus)

Infective Endocarditis

Recent untreated pharyngitis with Group A Streptococcus

History of intravenous drug use or recent invasive procedures

Elevated antistreptolysin O (ASO) titers without positive blood cultures

Positive blood cultures with causative bacteria

Post-infectious autoimmune reaction occurring weeks after initial infection

Subacute or acute persistent infection with continuous fever

Echocardiogram showing valvulitis or mitral valve regurgitation without vegetations

Echocardiogram showing vegetations on heart valves

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus) versus Juvenile Idiopathic Arthritis (JIA)

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus)

Juvenile Idiopathic Arthritis (JIA)

Acute arthritis following recent Group A Streptococcus pharyngitis in school-age children

Chronic arthritis onset typically before age 16 without preceding infection

Migratory arthritis resolving within days to weeks

Chronic joint inflammation lasting >6 weeks

Post-infectious autoimmune response with elevated ASO titers and evidence of molecular mimicry

Autoimmune arthritis with variable ANA positivity

Elevated ESR, CRP, and ASO titers indicating recent streptococcal infection

Normal or mildly elevated inflammatory markers without evidence of recent streptococcal infection

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus) versus Systemic Lupus Erythematosus (SLE)

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus)

Systemic Lupus Erythematosus (SLE)

Absence of ANA; presence of elevated ASO titers

Presence of antinuclear antibodies (ANA) and anti-dsDNA antibodies

Acute post-infectious syndrome with self-limited course

Chronic relapsing-remitting course with multisystem involvement

Normal complement levels with elevated inflammatory markers and ASO titers

Hypocomplementemia with positive lupus serologies

Preceding Group A Streptococcus pharyngitis

No preceding bacterial infection

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus) versus Kawasaki Disease

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus)

Kawasaki Disease

Typically affects children aged 5-15 years

Primarily affects children under 5 years old

Elevated ASO titers with normal or mildly elevated platelets

Elevated platelet count and sterile pyuria without elevated ASO titers

Fever with migratory polyarthritis and carditis following streptococcal infection

Fever lasting at least 5 days with mucocutaneous inflammation

Elevated ASO titers and evidence of recent Group A Streptococcus infection

No specific serologic test; diagnosis clinical

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus) versus Post-Streptococcal Glomerulonephritis

Rheumatic Fever (Streptococcus pyogenes - Group A Streptococcus)

Post-Streptococcal Glomerulonephritis

Follows Group A Streptococcus pharyngitis with systemic autoimmune features

Follows Group A Streptococcus skin infection or pharyngitis

Elevated ASO titers with normal complement and migratory arthritis

Hematuria, red blood cell casts, and low complement levels

Onset of arthritis, carditis, and chorea 2-4 weeks after infection

Acute nephritic syndrome developing 1-3 weeks after infection

No renal biopsy findings; diagnosis based on Jones criteria

Renal biopsy showing immune complex deposition

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.